Aerius occupies a niche market position serving cannabis industry clients who require specialized design and construction expertise for compliant facility buildouts. The company differentiates through regulatory expertise and financing capabilities, addressing a key barrier to entry in the heavily regulated cannabis sector. However, the company remains micro-cap with limited public visibility and financial disclosure.
Cyborg Score Rationale
Aerius operates in a niche, heavily regulated industry with limited scale indicators and sparse recent financial disclosure. The company is an OTC-traded micro-cap with minimal liquidity and public information availability. Regulatory changes to cannabis licensing and financing rules pose existential risk.
Top Insights
Founded in 2000, Aerius entered cannabis consulting early but remains micro-cap (OTC: AERS) with no recent disclosed revenue, limiting visibility into financial performance or market traction.
Serves a specialized segment—cannabis facility design, construction, and financing—where regulatory compliance is paramount; positioning could benefit from industry consolidation or legalization acceleration.
Absence of recent earnings, employee count, or public filings (last cited filing from 2014) indicates either minimal operations or severely limited public reporting, creating material uncertainty.
Named Competitors
Trulieve Cannabis — Largest U.S. cannabis retailer with operational compliance and site development expertise
Medbox Inc — Cannabis operator services including regulatory compliance consulting and facility design
Pono Capital Group — Cannabis consulting, development, and licensing services
Greenrose Capital — Cannabis consulting and operations advisory for licensed operators
Open the full interactive Aerius International Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.